In our studies, we found the Src inhibitor dasatinib not only effectively suppressed HuCCT1 cell migration [33] and invasion (Figure 1a) in a cultured system but also suppressed the HuCCT1 tumor development on SCID mice after a long-term treatment of dasatinib (Figure 3). Here, SRC is linked to neoplasm.